Revolution Medicines CEO to Speak at Investor Events
Mark Goldsmith will present at two healthcare conferences in November 2026, offering live webcasts for investors.
Updated on Oct. 27, 2026 in Biotech
Revolution Medicines CEO Mark Goldsmith is scheduled to participate in two separate investor conferences during November 2026. Both events will feature live webcasts available for public viewing.
Why it matters
Investor appearances by oncology executives often serve as a window into clinical development priorities and commercial strategy for pipeline assets. These sessions allow stakeholders to track updates from the Redwood City-based firm as it navigates the commercial-stage landscape.
The company will provide live webcasts for both appearances, with replays accessible for 14 days following each session. This availability window establishes a short-term access period for investors compared to the longer archival practices of some peer firms.
The players
Mark Goldsmith
Chief executive officer and chairman of Revolution Medicines.
Revolution Medicines
A Redwood City-based commercial-stage oncology company specializing in therapeutic development.
The details
Revolution Medicines focuses on the development of oncology therapies, currently operating as a commercial-stage organization. The scheduled presentations provide a venue for the company to detail its research and development progress. Participants will access these updates through live digital webcasts facilitated by the hosting organizations.
Timeline
November 2026: Mark Goldsmith participates in the 3rd Annual Guggenheim Healthcare Innovation Conference.
November 2026: Mark Goldsmith participates in the Jefferies Global Healthcare Conference in London.
Post-conference: Webcast replays available for at least 14 days.
The Tech Race
Participation in forums like the Guggenheim Healthcare Innovation Conference is a standard operational rhythm for commercial-stage biotech firms. These events serve as key competitive checkpoints for monitoring the research trajectory of oncology-focused drug pipelines.
Interested stakeholders can access the sessions through live webcasts hosted during the conference dates in November 2026. Following the events, recordings will remain available on the company website for a two-week period.
The takeaway
Investors should monitor the company investor events and presentations page for specific webcast start times and dial-in details. These presentations represent a consistent mechanism to gauge the firm's progress against its 2026 commercial oncology benchmarks.
Further reading
For broader trends in oncology research and development, explore our Biotech section.
More information
View the schedule and access webcasts on the company investor events and presentations page.
Source note: This article includes information reported by The Manila times.
